Compare MINISO Group Holding Ltd (MNSO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? MINISO Group Holding Ltd trades at $12.02 (market cap $3.74B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 35.5× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.32% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MNSO | VRTX | |
|---|---|---|
Market Cap | $3.74B | $132.79B |
Sector | Technology | Health |
52-Week High | $26.63 | $529.65 |
52-Week Low | $11.30 | $376.62 |
Enterprise Value | $4.41B | $126.92B |
Dividend Yield | 5.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $12.55, showing minimal daily movement (-0.08%). The stock exhibits neutral technical signals with bearish moving averages, trading near key support at $12. Fundamentally, the company reported strong Q1 2026 earnings that beat expectations with 28.5% revenue growth, though recent quarters showed mixed results. The company announced a HK$2 billion share repurchase program in June 2026, signaling management confidence in undervalued shares.
MNSO presents a compelling value opportunity with attractive valuation ratios (P/E 12.65, P/S 1.15) and improving profitability (2026 net margin projected at 8.98%). However, investors face risks from margin compression and volatile quarterly performance. With 75% analyst buy ratings and technical support at current levels, the stock offers upside potential but requires monitoring of execution consistency and competitive pressures.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
